There is a clinical need for targeted MRI-contrast agents that are more sensitive and specific in detection of glioma than conventional MRI contrast. We use interleukin-13 (IL-13) as targeting ligand because 75% of glioma cells overexpress IL-13Rα2 significantly1. We investigated the relative efficacy of liposomes conjugated with wild type IL-13 to a variant of IL-13, known as Targeted Quadruple Mutant13 (TQM-13) that has been shown to be more selective for the IL-13Rα2 and binds with higher affinity than the wide type. Our targeted MRI agent, TQM-13-liposomes-Gd, produced specific MRI contrast, delineating tumor, inflamed and normal tissues.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords